Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce Robinson

Showing results (141-150 of 167) with videos related to

Pageof 17
Sort By:
Thyroid : Official Journal of the American Thyroid Association|August 19, 2025
Patient-Reported Tolerability of Selpercatinib Compared to Cabozantinib/Vandetanib: A Secondary Analysis of the LIBRETTO-531 Randomized-Controlled Trial in <i>RET</i>-Mutant Medullary Thyroid CancerRossella Elisei, Lori J Wirth, Jaume Capdevila, et al.
The Journal of Pathology|April 4, 2017
Cousins not twins: intratumoural and intertumoural heterogeneity in syndromic neuroendocrine tumoursAidan Flynn, Trisha Dwight, Diana Benn, et al.
Lung Cancer (Amsterdam, Netherlands)|July 6, 2013
A genome-wide association study for malignant mesothelioma riskGemma Cadby, Sutapa Mukherjee, A W Bill Musk, et al.
Alzheimer Disease and Associated Disorders|December 7, 2002
Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain BankWarren W Barker, Cheryl A Luis, Alice Kashuba, et al.
Cancer|April 28, 2015
A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessmentMaria E Cabanillas, Martin Schlumberger, Barbara Jarzab, et al.
The New England Journal of Medicine|February 12, 2015
Lenvatinib versus placebo in radioiodine-refractory thyroid cancerMartin Schlumberger, Makoto Tahara, Lori J Wirth, et al.
Thyroid Research|June 16, 2025
The utility of <sup>68</sup>Ga-DOTATATE and <sup>18</sup>F-FDG PET/CT in predicting the response to tyrosine kinase inhibitors in patients with advanced medullary thyroid cancerEline C Jager, James McNeil, Alexander J Papachristos, et al.
Thyroid : Official Journal of the American Thyroid Association|August 22, 2025
2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid CancerMatthew D Ringel, Julie Ann Sosa, Zubair Baloch, et al.
Glomerular Diseases|November 29, 2023
Cure Glomerulonephropathy Pathology Classification and Core Scoring Criteria, Reproducibility, and Clinicopathologic CorrelationsMatthew B Palmer, Virginie Royal, J Charles Jennette, et al.
Journal of Medical Genetics|September 12, 2018
Bayesian approach to determining penetrance of pathogenic SDH variantsDiana E Benn, Ying Zhu, Katrina A Andrews, et al.
Pageof 17

Showing results (141-150 of 167) with videos related to

Sort By:
Pageof 17
Thyroid : Official Journal of the American Thyroid Association|August 19, 2025
Patient-Reported Tolerability of Selpercatinib Compared to Cabozantinib/Vandetanib: A Secondary Analysis of the LIBRETTO-531 Randomized-Controlled Trial in <i>RET</i>-Mutant Medullary Thyroid CancerRossella Elisei, Lori J Wirth, Jaume Capdevila, et al.
The Journal of Pathology|April 4, 2017
Cousins not twins: intratumoural and intertumoural heterogeneity in syndromic neuroendocrine tumoursAidan Flynn, Trisha Dwight, Diana Benn, et al.
Lung Cancer (Amsterdam, Netherlands)|July 6, 2013
A genome-wide association study for malignant mesothelioma riskGemma Cadby, Sutapa Mukherjee, A W Bill Musk, et al.
Alzheimer Disease and Associated Disorders|December 7, 2002
Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain BankWarren W Barker, Cheryl A Luis, Alice Kashuba, et al.
Cancer|April 28, 2015
A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessmentMaria E Cabanillas, Martin Schlumberger, Barbara Jarzab, et al.
The New England Journal of Medicine|February 12, 2015
Lenvatinib versus placebo in radioiodine-refractory thyroid cancerMartin Schlumberger, Makoto Tahara, Lori J Wirth, et al.
Thyroid Research|June 16, 2025
The utility of <sup>68</sup>Ga-DOTATATE and <sup>18</sup>F-FDG PET/CT in predicting the response to tyrosine kinase inhibitors in patients with advanced medullary thyroid cancerEline C Jager, James McNeil, Alexander J Papachristos, et al.
Thyroid : Official Journal of the American Thyroid Association|August 22, 2025
2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid CancerMatthew D Ringel, Julie Ann Sosa, Zubair Baloch, et al.
Glomerular Diseases|November 29, 2023
Cure Glomerulonephropathy Pathology Classification and Core Scoring Criteria, Reproducibility, and Clinicopathologic CorrelationsMatthew B Palmer, Virginie Royal, J Charles Jennette, et al.
Journal of Medical Genetics|September 12, 2018
Bayesian approach to determining penetrance of pathogenic SDH variantsDiana E Benn, Ying Zhu, Katrina A Andrews, et al.
Pageof 17